GL1X · GenesisL1 explorer

UniProt Q2N0S7

Envelope Glycoprotein gp41 (Q2N0S7)

Envelope Glycoprotein gp41 (UniProt Q2N0S7): 40 experimental structures on GenesisL1, 5 ligands bound, 218 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.

UniProt
Q2N0S7
Protein
Envelope Glycoprotein gp41
Experimental structures
40
Predicted models
0
Ligands
5
Pockets
218 · 25 records with a druggable one

Structures

40 records of Q2N0S7 in the MolNFT archive: 40 experimental, 0 predicted.

EntryTitleMethodChainsLigandsPockets
6CDECryo-EM structure at 3.8 A resolution of vaccine-elicited antibody vFP20.01 in complex with HIV-1…electron microscopyD, d, 1NAG8 (best 0.83)
6CDICryo-EM structure at 3.6 A resolution of vaccine-elicited antibody vFP16.02 in complex with HIV-1…electron microscopyc, A, DNAG, BMA—
6CH7XFEL crystal structure of a natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex…x-ray diffractionBNAG, FUC5 (best 0.61)
6CH7Xfel crystal structure of a natively-glycosylated BG505 SOSIP.664 HIV- 1 envelope trimer in complex…x-ray diffractionBNAG, FUC—
6CH8Crystal structure of a natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with…x-ray diffractionBNAG3 (best 0.67)
6CH8Crystal structure of a natively-glycosylated BG505 SOSIP.664 HIV-1 envelope trimer in complex with…x-ray diffractionBNAG—
6CHBCrystal structure of a natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with…x-ray diffractionB, A, C—6 (best 0.84)
6CHBCrystal structure of a natively-glycosylated BG505 SOSIP.664 HIV-1 envelope trimer in complex with…x-ray diffractionB, A, C——
6CM3BG505 SOSIP in complex with sCD4, 17b, 8ANC195electron microscopyA, B, CNAG9 (best 0.85)
6CM3BG505 sosip in complex with SCD4, 17B, 8ANC195electron microscopyA, B, CNAG—
6CRQGlutaraldehyde-treated BG505 SOSIP.664 Env in complex with PGV04 Fabelectron microscopyC, G, HNAG5 (best 0.84)
6CRQGlutaraldehyde-treated BG505 SOSIP.664 env in complex with PGV04 Fabelectron microscopyC, G, HNAG—
6CUECryo-EM structure at 4.0 A resolution of vaccine-elicited antibody vFP7.04 in complex with HIV-1…electron microscopy1, D, d—12 (best 0.82)
6CUFCryo-EM structure at 4.2 A resolution of vaccine-elicited antibody vFP1.01 in complex with HIV-1…electron microscopyD, A, cNAG9 (best 0.84)
6DE7Crystal Structure at 4.3 A Resolution of Glycosylated HIV-1 Clade A BG505 SOSIP.664 Prefusion Env…x-ray diffractionBNAG6 (best 0.57)
6DE7Crystal structure at 4.3 a resolution of glycosylated HIV-1 clade a BG505 SOSIP.664 prefusion env…x-ray diffractionBNAG—
6DIDHIV Env BG505 SOSIP with polyclonal Fabs from immunized rabbit #3417 post-boost#1electron microscopyB, I, JNAG6 (best 0.82)
6DIDHIV env BG505 sosip with polyclonal fabs from immunized rabbit #3417 post-BOOST#1electron microscopyB, I, JNAG—
6MARHIV-1 Envelope Glycoprotein Clone BG505 delCT N332T in complex with broadly neutralizing antibody…electron microscopyB, D, FNAG, GAL, FUC—
6MARHIV-1 envelope glycoprotein clone BG505 delct N332T in complex with broadly neutralizing antibody…electron microscopyB, D, FNAG, GAL, FUC—
6MN7Cryo-EM structure of BG505.SOSIP.664 in complex with BF520.1 antigen binding fragmentelectron microscopyB, E, FNAG5 (best 0.89)
6MN7Cryo-EM structure of BG505.SOSIP.664 in complex with BF520.1 antigen binding fragmentelectron microscopyB, E, FNAG—
6MPGCryo-EM structure at 3.2 A resolution of HIV-1 fusion peptide-directed antibody, A12V163-b.01…electron microscopyU, A, DNAG—
6MPHCryo-EM structure at 3.8 A resolution of HIV-1 fusion peptide-directed antibody, DF1W-a.01…electron microscopy6, D, ENAG10 (best 0.83)
6N1WCryo-EM structure at 4.2 A resolution of vaccine-elicited antibody DFPH-a.15 in complex with HIV-1…electron microscopyA, D, d—11 (best 0.81)
6UM5Cryo-EM structure of HIV-1 neutralizing antibody DH270 UCA3 in complex with CH848 10.17DT envelectron microscopyB, F, J—10 (best 0.79)
6UM6Cryo-EM structure of HIV-1 neutralizing antibody DH270.6 in complex with CH848 10.17DT Envelectron microscopyB, F, J—7 (best 0.83)
6UM6Cryo-EM structure of HIV-1 neutralizing antibody DH270.6 in complex with CH848 10.17DT envelectron microscopyB, F, J—7 (best 0.83)
6UM7Cryo-EM structure of vaccine-elicited HIV-1 neutralizing antibody DH270.mu1 in complex with CH848…electron microscopyH, D, 1NAG7 (best 0.79)
6UM7Cryo-EM structure of vaccine-elicited HIV-1 neutralizing antibody DH270.MU1 in complex with CH848…electron microscopyH, D, 1NAG7 (best 0.79)
6V8ZVRC03 and 10-1074 Bound BG505 F14 HIV-1 SOSIP Envelope Trimer Structureelectron microscopyB, H, NNAG10 (best 0.84)
6V8ZVRC03 and 10-1074 bound BG505 F14 HIV-1 sosip envelope trimer structureelectron microscopyB, H, NNAG—
7LL1Cryo-EM structure of BG505 DS-SOSIP in complex with glycan276-dependent broadly neutralizing…electron microscopyB, D, INAG, BMA13 (best 0.83)
7LL1Cryo-EM structure of BG505 ds-sosip in complex with GLYCAN276- dependent broadly neutralizing…electron microscopyB, D, INAG, BMA—
7LL2Cryo-EM structure of BG505 DS-SOSIP in complex with Glycan276-Dependent Broadly Neutralizing…electron microscopyB, D, FNAG9 (best 0.80)
7LL2Cryo-EM structure of BG505 ds-sosip in complex with GLYCAN276- dependent broadly neutralizing…electron microscopyB, D, FNAG—
7N65Complex structure of HIV superinfection Fab QA013.2 and BG505.SOSIP.664electron microscopyB, F, JNAG, BMA12 (best 0.81)
8FR6Antibody vFP53.02 in complex with HIV-1 envelope trimer BG505 DS-SOSIPelectron microscopyA, B, FNAG14 (best 0.83)
8G4MVaccine-elicited human antibody 2C06 in complex with HIV-1 envelope trimer BG505 DS-SOSIPelectron microscopyA, B, FNAG, MAN14 (best 0.82)
8G4TVaccine-elicited human antibody 2C09 in complex with HIV-1 envelope trimer BG505 DS-SOSIPelectron microscopyA, B, FNAG13 (best 0.80)

Ligands

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · in 33 records
  • BMA · beta-D-mannopyranose · in 4 records
  • FUC · alpha-L-fucopyranose · in 4 records
  • GAL · beta-D-galactopyranose · in 2 records
  • MAN · alpha-D-mannopyranose · in 1 record

Elsewhere

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.